KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Acadia Pharmaceuticals (ACAD) over the last 3 years, with Sep 2025 value amounting to $12.5 million.

  • Acadia Pharmaceuticals' Gains from Investment Securities was N/A to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year change of. This contributed to the annual value of $146.5 million for FY2024, which is 781.24% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $12.5 million for Q3 2025, which was down 24.73% from $16.6 million recorded in Q4 2023.
  • Acadia Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $16.6 million during Q4 2023, with a 5-year trough of $12.5 million in Q3 2025.
  • Over the past 2 years, Acadia Pharmaceuticals' median Gains from Investment Securities value was $14.6 million (recorded in 2023), while the average stood at $14.6 million.
  • Data for Acadia Pharmaceuticals' Gains from Investment Securities shows a peak YoY spiked of 34.46% (in 2021) over the last 5 years.
  • Acadia Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $15.1 million in 2021, then rose by 8.31% to $16.3 million in 2022, then rose by 1.75% to $16.6 million in 2023, then reached $12.5 million in 2025.
  • Its Gains from Investment Securities stands at $12.5 million for Q3 2025, versus $16.6 million for Q4 2023 and $16.3 million for Q4 2022.